Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network: Clinical Trials Development & Member Site Core

Information

  • Research Project
  • 9627270
  • ApplicationId
    9627270
  • Core Project Number
    U10CA180863
  • Full Project Number
    2U10CA180863-06
  • Serial Number
    180863
  • FOA Number
    RFA-CA-17-058
  • Sub Project Id
    8059
  • Project Start Date
    -
  • Project End Date
    -
  • Program Officer Name
  • Budget Start Date
    3/1/2019 - 5 years ago
  • Budget End Date
    2/29/2020 - 4 years ago
  • Fiscal Year
    2019
  • Support Year
    06
  • Suffix
  • Award Notice Date
    4/2/2019 - 5 years ago

Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network: Clinical Trials Development & Member Site Core

Summary The transformational advances in cancer biology and technologies to characterize cancers at a molecular level, combined with the rapid expansion of novel drugs and cellular therapies, mandates a fundamental re- evaluation of clinical trial design and delivery to ensure maximal patient and societal benefits. The Canadian Cancer Trials Group (CCTG) has strong partnerships with US investigators and groups within the NCTN, which emphasize international collaboration to conduct definitive practice-changing trials, trials in rare cancers settings, and trials testing precision-medicine strategies. As the Canadian Collaborating Clinical Trials Network (CCCTN) of the NCTN, CCTG expands NCTN's scientific expertise by: 1) Involving the best and brightest within its network in NCTN leadership roles; 2) Increasing clinical trial capacity through its national network, which includes all centres in Canada; and, 3) Facilitates access to Canadian patients, which is particularly important for trials testing interventions in rare populations. CCTG contributes to scientific concept development, accrual, biospecimen collection, and network leadership, and has expertise in instrumental components of trial conduct (including information technology and regulations). CCTG develops and participates in NCTN adult cancer trial portfolios in breast, lung, urological, and gastrointestinal malignancies, in uncommon/rare settings of unmet need such as hematological, skin, brain and head and neck cancers, and includes adolescents and young adults on AYA trials. In addition, CCTG capitalizes on opportunities to extend its scope of trial activity to include surgical and lifestyle interventions and imaging and digital health endpoints. Research incorporates translational science and other correlative endpoints to enrich information derived from NCTN trials and methods and technology development to improve clinical trial designs, endpoints, and execution. Finally, CCTG contributes trial datasets from NCTN trials as part of its data sharing policy. As the CCCTN, CCTG, Canada's largest and most experienced clinical trials unit, creates and delivers innovative strategies that arise from the NCTN accelerating the translation of scientific advances into improvements in cancer treatments improving the lives of children, adolescents, and adults diagnosed with cancer.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    U10
  • Administering IC
    CA
  • Application Type
    2
  • Direct Cost Amount
    1007400
  • Indirect Cost Amount
    36352
  • Total Cost
  • Sub Project Total Cost
    518293
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NCI:518293\
  • Funding Mechanism
    OTHER RESEARCH-RELATED
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    QUEEN'S UNIVERSITY AT KINGSTON
  • Organization Department
  • Organization DUNS
    207884032
  • Organization City
    KINGSTON
  • Organization State
    ON
  • Organization Country
    CANADA
  • Organization Zip Code
    K7L 3N6
  • Organization District
    CANADA